Your browser doesn't support javascript.
loading
A Randomized Trial of a Composite T2-Biomarker Strategy Adjusting Corticosteroid Treatment in Severe Asthma: A Post Hoc Analysis by Sex.
Eastwood, Matthew C; Busby, John; Jackson, David J; Pavord, Ian D; Hanratty, Catherine E; Djukanovic, Ratko; Woodcock, Ashley; Walker, Samantha; Hardman, Timothy C; Arron, Joseph R; Choy, David F; Bradding, Peter; Brightling, Chris E; Chaudhuri, Rekha; Cowan, Douglas; Mansur, Adel H; Fowler, Stephen J; Howarth, Peter; Lordan, James; Menzies-Gow, Andrew; Harrison, Timothy; Robinson, Douglas S; Holweg, Cecile T J; Matthews, John G; Heaney, Liam G.
Affiliation
  • Eastwood MC; Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University, Belfast, United Kingdom.
  • Busby J; Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University, Belfast, United Kingdom.
  • Jackson DJ; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
  • Pavord ID; Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Hanratty CE; Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University, Belfast, United Kingdom.
  • Djukanovic R; NIHR Southampton Biomedical Research Centre, University of Southampton, Southampton, United Kingdom.
  • Woodcock A; Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, United Kingdom.
  • Walker S; Asthma UK, London, United Kingdom.
  • Hardman TC; Niche Science & Technology, Richmond, United Kingdom.
  • Arron JR; Genentech, Inc, South San Francisco, Calif.
  • Choy DF; Genentech, Inc, South San Francisco, Calif.
  • Bradding P; Department of Infection, Immunity and Inflammation, Institute for Lung Health, University of Leicester, Leicester, United Kingdom.
  • Brightling CE; Department of Infection, Immunity and Inflammation, Institute for Lung Health, University of Leicester, Leicester, United Kingdom.
  • Chaudhuri R; NHS Greater Glasgow and Clyde Health Board, Gartnavel Hospital, Glasgow, United Kingdom; NHS Greater Glasgow and Clyde, Stobhill Hospital, Glasgow, United Kingdom.
  • Cowan D; NHS Greater Glasgow and Clyde, Stobhill Hospital, Glasgow, United Kingdom.
  • Mansur AH; University of Birmingham and Heartlands Hospital, Heart of England NHS Foundation Trust, Birmingham, United Kingdom.
  • Fowler SJ; Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, United Kingdom.
  • Howarth P; School of Clinical and Experimental Sciences, University of Southampton, NIHR Southampton Biomedical Research Centre, Southampton, United Kingdom.
  • Lordan J; The Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.
  • Menzies-Gow A; Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom.
  • Harrison T; UK Nottingham Respiratory NIHR Biomedical Research Centre, University of Nottingham, Nottingham, United Kingdom.
  • Robinson DS; University College Hospitals NHS Foundation Trust, London, United Kingdom.
  • Holweg CTJ; Genentech, Inc, South San Francisco, Calif.
  • Matthews JG; Peter Gorer Department of Immunobiology, King's College, London, United Kingdom; 23andMe, Sunnyvale, Calif.
  • Heaney LG; Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University, Belfast, United Kingdom. Electronic address: l.heaney@qub.ac.uk.
J Allergy Clin Immunol Pract ; 11(4): 1233-1242.e5, 2023 04.
Article de En | MEDLINE | ID: mdl-36621603
ABSTRACT

BACKGROUND:

Approximately 5% to 10% of patients with asthma have severe disease, with a consistent preponderance in females. Current asthma guidelines recommend stepwise treatment to achieve symptom control with no differential treatment considerations for either sex.

OBJECTIVE:

To examine whether patient sex affects outcomes when using a composite T2-biomarker score to adjust corticosteroid (CS) treatment in patients with severe asthma compared with standard care.

METHODS:

This is a post hoc analysis, stratifying patient outcomes by sex, of a 48-week, multicenter, randomized controlled clinical trial comparing a biomarker-defined treatment algorithm with standard care. The primary outcome was the proportion of patients with a reduction in CS treatment (inhaled and oral corticosteroids). Secondary outcomes included exacerbation rates, hospital admissions, and lung function.

RESULTS:

Of the 301 patients randomized, 194 (64.5%) were females and 107 (35.5%) were males. The biomarker algorithm led to a greater proportion of females being on a lower CS dose versus standard care, which was not seen in males (effect estimate females, 3.57; 95% CI, 1.14-11.18 vs males, 0.54; 95% CI, 0.16-1.80). In T2-biomarker-low females, reducing CS dose was not associated with increased exacerbations. Females scored higher in all domains of the 7-item Asthma Control Questionnaire, apart from FEV1, but with no difference when adjusted for body mass index/anxiety and/or depression. Dissociation between symptoms and T2 biomarkers were noted in both sexes, with a higher proportion of females being symptom high/T2-biomarker low (22.8% vs 15.6%; P = .0002), whereas males were symptom low/T2-biomarker high (22.3% vs 11.4%; P < .0001).

CONCLUSIONS:

This exploratory post hoc analysis identified that females achieved a greater benefit from biomarker-directed CS optimization versus symptom-directed treatment.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Asthme / Antiasthmatiques Type d'étude: Clinical_trials / Guideline / Prognostic_studies / Qualitative_research Limites: Female / Humans / Male Langue: En Journal: J Allergy Clin Immunol Pract Année: 2023 Type de document: Article Pays d'affiliation: Royaume-Uni

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Asthme / Antiasthmatiques Type d'étude: Clinical_trials / Guideline / Prognostic_studies / Qualitative_research Limites: Female / Humans / Male Langue: En Journal: J Allergy Clin Immunol Pract Année: 2023 Type de document: Article Pays d'affiliation: Royaume-Uni